Flow cytometry as a fast, cost-effective tool to assess IGHV mutational status in CLL

Blood Adv. 2023 Sep 12;7(17):4701-4704. doi: 10.1182/bloodadvances.2022008033.
No abstract available

MeSH terms

  • Cost-Benefit Analysis
  • Flow Cytometry
  • Humans
  • Immunoglobulin Heavy Chains / genetics
  • Leukemia, Lymphocytic, Chronic, B-Cell* / diagnosis
  • Leukemia, Lymphocytic, Chronic, B-Cell* / genetics
  • Mutation

Substances

  • Immunoglobulin Heavy Chains